Elixiron Immunotherapeutics, Inc., a company developing therapeutics for cancer, neurological diseases and inflammatory disorders, closed a $27m Series A-1 extension financing round, bringing the total Series A-1 raise to $27m.
The round was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
Founded in 2017 and led by Hung-Kai Chen, Founder, CEO and Chairman of the Board, Elixiron is a biotechnology company with operations in San Francisco, Taipei and Shanghai on a mission to develop next-generation immunotherapies for neurodegenerative and immunological disorders, as well as cancer, by tapping into what human clinical findings can teach us for reverse-translational medicine approaches.
The company intends to use the funds to advance phase 1 trials of two pipeline candidates and take three immuno-oncology assets towards IND applications.
- EI-1071 is an orally available, highly potent Colony-Stimulating Factor 1 Receptor inhibitor that is in a phase 1 trial in part thanks to an Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program award.
- EI-001 is a fully human antibody that neutralizes an immuno-modulatory target of interest in Vitiligo and some other immunological disorders including Chronic Hepatitis B.
The executive team includes:
- Pandelakis Koni, Executive Vice President of R&D, formerly Director of Research at the Parker Institute for Cancer Immunotherapy, and
- Carrie Duan, Executive Vice President of Clinical Development, who previously had leading roles in clinical development and medical affairs management with AstraZeneca, Bayer, GSK and other multinational companies.